JRE #2467 - Michael Pollan · Aired Mar 14, 2026
Claim summary · not a verbatim quotation
MDMA and psilocybin therapist expedited approval was recently stalled by a removal from a White House priority list.
The finding
What the evidence shows
This is grounded in something real: in October 2025, the White House and HHS blocked FDA Commissioner Marty Makary's plan to give Compass Pathways' psilocybin treatment an expedited 'National Priority Voucher,' pulling it from the list right before recipients were announced, as first reported by STAT News in February 2026. But that specific block was about psilocybin. MDMA therapy's setback traces to a different event, the FDA's August 2024 rejection of Lykos Therapeutics's MDMA application, so folding MDMA into the same 'removed from a White House list' story overstates what actually happened to it.
Read the supporting source · www.statnews.com ↗Quick answer & review status
Quick answer
Is it true that MDMA and psilocybin therapist expedited approval was recently stalled by a removal from a White House priority list?
Partly. The claim stretches what the evidence shows. This is grounded in something real: in October 2025, the White House and HHS blocked FDA Commissioner Marty Makary's plan to give Compass Pathways' psilocybin treatment an expedited 'National Priority Voucher,' pulling it from the list right before recipients were announced, as first reported by STAT News in February 2. It was said on JRE #2467 - Michael Pollan, aired Mar 14, 2026, at 13:30. We haven't independently confirmed who said it. The supporting source is statnews.com, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.